SAFETY DATA SHEET
according to the Hazardous Products Regulations

Prednisolone / Neomycin / Tetracycline / Bacitracin Formulation

Version 8.0  Revision Date: 09/26/2023  SDS Number: 407505-00022  Date of last issue: 04/04/2023
Date of first issue: 01/07/2016

SECTION 1. IDENTIFICATION

Product name: Prednisolone / Neomycin / Tetracycline / Bacitracin Formulation
Other means of identification: No data available

Manufacturer or supplier's details
Company name of supplier: Merck & Co., Inc
Address: 126 E. Lincoln Avenue
Rahway, New Jersey U.S.A. 07065
Telephone: 908-740-4000
Emergency telephone: 1-908-423-6000
E-mail address: EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use
Recommended use: Veterinary product
Restrictions on use: Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the Hazardous Products Regulations
Skin sensitization: Category 1
Reproductive toxicity: Category 1A

Effects on or via lactation
Specific target organ toxicity
- repeated exposure: Category 2 (Kidney, inner ear)
Specific target organ toxicity
- repeated exposure (Oral): Category 2 (Gastrointestinal tract, Nervous system, Skin, Teeth)

GHS label elements
Hazard pictograms:
Signal Word: Danger
Hazard Statements: H317 May cause an allergic skin reaction.
H360D May damage the unborn child.
H362 May cause harm to breast-fed children.
H373 May cause damage to organs (Kidney, inner ear) through prolonged or repeated exposure.
H373 May cause damage to organs (Gastrointestinal tract, Nervous system, Skin, Teeth) through prolonged or repeated exposure if swallowed.
Precautionary Statements:

**Prevention:**
- P201 Obtain special instructions before use.
- P202 Do not handle until all safety precautions have been read and understood.
- P260 Do not breathe dust.
- P263 Avoid contact during pregnancy and while nursing.
- P264 Wash skin thoroughly after handling.
- P270 Do not eat, drink or smoke when using this product.
- P272 Contaminated work clothing should not be allowed out of the workplace.
- P280 Wear protective gloves, protective clothing, eye protection and face protection.

**Response:**
- P302 + P352 IF ON SKIN: Wash with plenty of water.
- P308 + P313 IF exposed or concerned: Get medical attention.
- P333 + P313 If skin irritation or rash occurs: Get medical attention.
- P362 + P364 Take off contaminated clothing and wash it before reuse.

**Storage:**
- P405 Store locked up.

**Disposal:**
- P501 Dispose of contents and container to an approved waste disposal plant.

**Other hazards**

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

### SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

**Substance / Mixture**:
- Mixture

**Components**

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>Common Name/Synonym</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paraffin waxes and Hydrocarbon waxes</td>
<td>No data available</td>
<td>8002-74-2</td>
<td>87.7</td>
</tr>
<tr>
<td>Neomycin, sulfate (salt)</td>
<td>No data available</td>
<td>1405-10-3</td>
<td>4.6</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>Octadecanoic acid, magnesium salt (2:1)</td>
<td>557-04-0</td>
<td>4.6</td>
</tr>
<tr>
<td>Tetracycline hydrochloride</td>
<td>No data available</td>
<td>64-75-5</td>
<td>2.43</td>
</tr>
<tr>
<td>Bacitracin</td>
<td>Altracin</td>
<td>1405-87-4</td>
<td>0.365</td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET
according to the Hazardous Products Regulations

Prednisolone / Neomycin / Tetracycline / Bacitracin Formulation

<table>
<thead>
<tr>
<th>Substance</th>
<th>EC Number</th>
<th>NF Number</th>
<th>NF Number CR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prednisolone</td>
<td></td>
<td>50-24-8</td>
<td>0.126</td>
</tr>
</tbody>
</table>

SECTION 4. FIRST AID MEASURES

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air. Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed:
- May cause an allergic skin reaction.
- May damage the unborn child.
- May cause harm to breast-fed children.
- May cause damage to organs through prolonged or repeated exposure.
- Contact with dust can cause mechanical irritation or drying of the skin.
- Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media: Water spray
- Alcohol-resistant foam
- Carbon dioxide (CO2)
- Dry chemical

Unsuitable extinguishing media: None known.

Specific hazards during firefighting: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides
- Nitrogen oxides (NOx)
- Chlorine compounds
Metal oxides
Sulfur oxides

Specific extinguishing methods:
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

Special protective equipment for fire-fighters:
In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures:
Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions:
Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up:
Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures:
Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation:
If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling:
Avoid contact during pregnancy and while nursing. Do not get on skin or clothing. Do not breathe dust. Do not swallow. Avoid contact with eyes. Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
Keep container tightly closed.
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage:
- Keep in properly labeled containers.
- Store locked up.
- Keep tightly closed.
- Store in accordance with the particular national regulations.

Materials to avoid:
- Do not store with the following product types:
  - Strong oxidizing agents
  - Self-reactive substances and mixtures
  - Organic peroxides
  - Explosives
  - Gases

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

**Ingredients with workplace control parameters**

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
</table>
| Paraffin waxes and Hydrocarbon waxes | 8002-74-2 | TWA (Fumes)| 2 mg/m³                                        | CA AB OEL  
|                                    |           | TWA (Fumes)| 2 mg/m³                                        | CA BC OEL  
|                                    |           | TWA (Fumes)| 2 mg/m³                                        | CA QC OEL  
|                                    |           | TWA (Fumes)| 2 mg/m³                                        | ACGIH      
| Neomycin, sulfate (salt)           | 1405-10-3 | TWA        | 1 mg/m³ (OEB 1)                                | Internal   
|                                    |           | Wipe limit | 0.1 mg/100 cm²                                 | Internal   
| Magnesium stearate                 | 557-04-0  | TWA        | 10 mg/m³                                       | CA AB OEL  
|                                    |           | TWA (Inhalable) | 10 mg/m³                                      | CA BC OEL  
|                                    |           | TWA (Respirable) | 3 mg/m³                                     | CA BC OEL  
|                                    |           | TWA (Inhalable particulate matter) | 10 mg/m³                                     | ACGIH      
|                                    |           | TWA        | 3 mg/m³                                        | ACGIH      

Further information: DSEN, OTO
SAFETY DATA SHEET
according to the Hazardous Products Regulations

Prednisolone / Neomycin / Tetracycline / Bacitracin Formulation

Version 8.0  Revision Date: 09/26/2023  SDS Number: 407505-00022  Date of last issue: 04/04/2023
Date of first issue: 01/07/2016

### (Respirable particulate matter)

<table>
<thead>
<tr>
<th>Compound</th>
<th>TWA</th>
<th>Limit</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tetracycline hydrochloride</td>
<td>64-75-5</td>
<td>0.9 mg/m³</td>
<td>Internal</td>
</tr>
<tr>
<td>Bacitracin</td>
<td>1405-87-4</td>
<td>4 mg/m³</td>
<td>Internal</td>
</tr>
<tr>
<td>Prednisolone</td>
<td>50-24-8</td>
<td>10 µg/m³</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Further information: DSEN, RSEN

Wipe limit 0.1 mg/100 cm² Internal

### Engineering measures
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

### Personal protective equipment

#### Respiratory protection
If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type: Particulates type

#### Hand protection
Material: Chemical-resistant gloves

#### Remarks
Consider double gloving.

#### Eye protection
Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

#### Skin and body protection
Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially contaminated clothing.

#### Hygiene measures
If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.

When using do not eat, drink or smoke.

Contaminated work clothing should not be allowed out of the workplace.

Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures,
industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder
Color : No data available
Odor : No data available
Odor Threshold : No data available
pH : No data available
Melting point/freezing point : No data available
Initial boiling point and boiling range : No data available
Flash point : Not applicable
Evaporation rate : Not applicable
Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids) : Not applicable
Upper explosion limit / Upper flammability limit : No data available
Lower explosion limit / Lower flammability limit : No data available
Vapor pressure : Not applicable
Relative vapor density : Not applicable
Relative density : No data available
Density : No data available
Solubility(ies)
  Water solubility : No data available
Partition coefficient: n-octanol/water : Not applicable
Autoignition temperature : No data available
Decomposition temperature : No data available
Viscosity
SAFETY DATA SHEET
according to the Hazardous Products Regulations

Prednisolone / Neomycin / Tetracycline / Bacitracin Formulation

Viscosity, kinematic  : Not applicable
Explosive properties  : Not explosive
Oxidizing properties  : The substance or mixture is not classified as oxidizing.
Molecular weight      : No data available
Particle size         : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions
May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure
Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Product:
Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Components:
Paraffin waxes and Hydrocarbon waxes:

Acute oral toxicity
LD50 (Rat): > 5,000 mg/kg
Method: OECD Test Guideline 420

Acute dermal toxicity
LD50 (Rabbit): > 3,600 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity
Neomycin, sulfate (salt):
- **Acute oral toxicity**
  - LD50 (Mouse): 2,880 mg/kg
  - LD50 (Rat): 2,750 mg/kg
- **Acute toxicity (other routes of administration)**
  - LD50 (Rat): 633 mg/kg
  - Application Route: Subcutaneous
  - LD50 (Mouse): 116 mg/kg
  - Application Route: Intraperitoneal
  - LD50 (Mouse): 27.6 mg/kg
  - Application Route: Intravenous
  - LD50 (Mouse): 275 mg/kg
  - Application Route: Subcutaneous

Magnesium stearate:
- **Acute oral toxicity**
  - LD50 (Rat): > 2,000 mg/kg
  - Method: OECD Test Guideline 423
  - Assessment: The substance or mixture has no acute oral toxicity
  - Remarks: Based on data from similar materials
- **Acute dermal toxicity**
  - LD50 (Rabbit): > 2,000 mg/kg
  - Remarks: Based on data from similar materials

Tetracycline hydrochloride:
- **Acute oral toxicity**
  - LD50 (Rat): 6,443 mg/kg
  - LD50 (Mouse): 2,759 mg/kg
- **Acute toxicity (other routes of administration)**
  - LD50 (Rat): 128 mg/kg
  - Application Route: Intravenous
  - LD50 (Mouse): 157 mg/kg
  - Application Route: Intravenous

Bacitracin:
- **Acute oral toxicity**
  - LD50 (Mouse): > 2,000 mg/kg
  - Remarks: Based on data from similar materials

Prednisolone:
- **Acute oral toxicity**
  - LD50 (Mouse): 1,680 mg/kg
  - LD50 (Rat): > 3,857 mg/kg
- **Acute inhalation toxicity**
  - Remarks: No data available
SAFETY DATA SHEET
according to the Hazardous Products Regulations

Prednisolone / Neomycin / Tetracycline / Bacitracin Formulation

Version 8.0  Revision Date: 09/26/2023  SDS Number: 407505-00022  Date of last issue: 04/04/2023
Date of first issue: 01/07/2016

Acute dermal toxicity  Remarks: No data available
Acute toxicity (other routes of administration)
LD50 (Rat): 147 mg/kg
Application Route: Subcutaneous
LD50 (Mouse): 767 mg/kg
Application Route: Intraperitoneal

Skin corrosion/irritation
Not classified based on available information.

Components:
Paraffin waxes and Hydrocarbon waxes:
Species: Rabbit
Method: OECD Test Guideline 404
Result: No skin irritation

Neomycin, sulfate (salt):
Species: Rabbit
Result: Mild skin irritation

Magnesium stearate:
Species: Rabbit
Result: No skin irritation
Remarks: Based on data from similar materials

Tetracycline hydrochloride:
Remarks: No data available

Prednisolone:
Remarks: No data available

Serious eye damage/eye irritation
Not classified based on available information.

Components:
Paraffin waxes and Hydrocarbon waxes:
Species: Rabbit
Result: No eye irritation
Method: OECD Test Guideline 405

Neomycin, sulfate (salt):
Species: Rabbit
Result: No eye irritation
Magnesium stearate:
Species: Rabbit
Result: No eye irritation
Remarks: Based on data from similar materials

Tetracycline hydrochloride:
Remarks: No data available

Prednisolone:
Remarks: No data available

Respiratory or skin sensitization
Skin sensitization
May cause an allergic skin reaction.
Respiratory sensitization
Not classified based on available information.

Components:
Paraffin waxes and Hydrocarbon waxes:
Test Type: Maximization Test
Routes of exposure: Skin contact
Species: Guinea pig
Method: OECD Test Guideline 406
Result: negative

Neomycin, sulfate (salt):
Routes of exposure: Dermal
Species: Humans
Result: positive

Magnesium stearate:
Test Type: Maximization Test
Routes of exposure: Skin contact
Species: Guinea pig
Method: OECD Test Guideline 406
Result: negative
Remarks: Based on data from similar materials

Tetracycline hydrochloride:
Remarks: No data available

Bacitracin:
Test Type: Human repeat insult patch test (HRIPT)
Routes of exposure: Skin contact
Result: positive
<table>
<thead>
<tr>
<th>Component</th>
<th>Genotoxicity in vitro</th>
<th>Genotoxicity in vivo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paraffin waxes and Hydrocarbon waxes:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prednisolone:</td>
<td>Test Type: Chromosome aberration test in vitro Result: negative</td>
<td></td>
</tr>
<tr>
<td>Neomycin, sulfate (salt):</td>
<td>Test Type: Bacterial reverse mutation assay (AMES) Result: negative</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Test Type: In vitro mammalian cell gene mutation test Test system: Chinese hamster ovary cells Result: negative</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Test Type: Chromosomal aberration Test system: Human lymphocytes Result: positive</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Test Type: In vitro micronucleus test Result: negative</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Test Type: Cytogenetic assay Species: Mouse Cell type: Bone marrow Application Route: Intravenous injection Result: negative</td>
<td></td>
</tr>
<tr>
<td>Magnesium stearate:</td>
<td>Test Type: In vitro mammalian cell gene mutation test Result: negative Remarks: Based on data from similar materials</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Test Type: Chromosome aberration test in vitro Method: OECD Test Guideline 473</td>
<td></td>
</tr>
<tr>
<td>Compound</td>
<td>Genotoxicity in vitro</td>
<td>Genotoxicity in vivo</td>
</tr>
<tr>
<td>--------------------------</td>
<td>-----------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>Tetracycline hydrochloride</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test Type: Bacterial reverse mutation assay (AMES)</td>
<td>Result: negative</td>
<td>Remarks: Based on data from similar materials</td>
</tr>
<tr>
<td>Test Type: Cytogenetic assay</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test system: Chinese hamster ovary cells</td>
<td>Result: negative</td>
<td></td>
</tr>
<tr>
<td>Test Type: sister chromatid exchange assay</td>
<td>Result: negative</td>
<td></td>
</tr>
<tr>
<td>Test Type: Mouse Lymphoma</td>
<td>Result: negative</td>
<td></td>
</tr>
<tr>
<td>Bacitracin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test Type: Bacterial reverse mutation assay (AMES)</td>
<td>Result: negative</td>
<td>Remarks: Based on data from similar materials</td>
</tr>
<tr>
<td>Test Type: In vitro mammalian cell gene mutation test</td>
<td>Result: negative</td>
<td>Remarks: Based on data from similar materials</td>
</tr>
<tr>
<td>Test Type: Chromosome aberration test in vitro</td>
<td>Result: negative</td>
<td>Remarks: Based on data from similar materials</td>
</tr>
<tr>
<td>Prednisolone</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test Type: Bacterial reverse mutation assay (AMES)</td>
<td>Result: negative</td>
<td></td>
</tr>
<tr>
<td>Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Species: Rat</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Application Route: Oral</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Result: negative</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Prednisolone / Neomycin / Tetracycline / Bacitracin Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.0</td>
<td>09/26/2023</td>
<td>407505-00022</td>
<td>04/04/2023</td>
<td>01/07/2016</td>
</tr>
</tbody>
</table>

**Test Type:** sister chromatid exchange assay  
**Species:** Humans  
**Result:** negative

### Carcinogenicity
Not classified based on available information.

### Components:

**Paraffin waxes and Hydrocarbon waxes:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>Ingestion</td>
<td>2 Years</td>
<td>negative</td>
</tr>
</tbody>
</table>

**Neomycin, sulfate (salt):**

<table>
<thead>
<tr>
<th>Species</th>
<th>Exposure time</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>2 Years</td>
<td>negative</td>
</tr>
</tbody>
</table>

**Tetracycline hydrochloride:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>Oral</td>
<td>103 W</td>
<td>negative</td>
</tr>
<tr>
<td>Mouse</td>
<td>Oral</td>
<td>103 W</td>
<td>negative</td>
</tr>
</tbody>
</table>

**Prednisolone:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>Oral</td>
<td>18 Months</td>
<td>negative</td>
</tr>
</tbody>
</table>

### Reproductive toxicity
May damage the unborn child.  
May cause harm to breast-fed children.

### Components:

**Paraffin waxes and Hydrocarbon waxes:**

| Effects on fertility | Test Type: Reproduction/Developmental toxicity screening test  
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Species</td>
<td>Rat</td>
<td>Result: negative</td>
</tr>
<tr>
<td>Application Route</td>
<td>Ingestion</td>
<td>Remarks: Based on data from similar materials</td>
</tr>
</tbody>
</table>
Effects on fetal development:
- Test Type: Fertility/early embryonic development
- Species: Rat
- Application Route: Skin contact
- Result: negative
- Remarks: Based on data from similar materials

Neomycin, sulfate (salt):
Effects on fertility:
- Test Type: Three-generation reproduction toxicity study
- Species: Rat
- Application Route: Oral
- General Toxicity Parent: NOAEL: 25 mg/kg body weight
- Result: No effects on fertility and early embryonic development were detected.

Effects on fetal development:
- Test Type: Embryo-fetal development
- Species: Rat
- Application Route: Oral
- Embryo-fetal toxicity.: NOAEL: 275 mg/kg body weight
- Result: No adverse effects., No teratogenic effects.

Reproductive toxicity - Assessment:
- Some evidence of adverse effects on development, based on animal experiments.

Magnesium stearate:
Effects on fertility:
- Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
- Species: Rat
- Application Route: Ingestion
- Method: OECD Test Guideline 422
- Result: negative
- Remarks: Based on data from similar materials

Effects on fetal development:
- Test Type: Embryo-fetal development
- Species: Rat
- Application Route: Ingestion
- Result: negative
- Remarks: Based on data from similar materials

Tetracycline hydrochloride:
Effects on fertility:
- Test Type: Fertility
- Species: Rat
- Application Route: Oral
- Fertility: NOAEL: 400 mg/kg body weight
Prenilone / Neomycin / Tetracycline / Bacitracin Formulation

Result: No effects on fertility.

Effects on fetal development:
- Test Type: Development

Reproductive toxicity - Assessment:
- Studies indicating a hazard to babies during the lactation period, May damage the unborn child.

Bacitracin:
- Effects on fertility:
  - Test Type: Fertility/early embryonic development
  - Species: Rat
  - Application Route: Ingestion
  - Result: negative
  - Remarks: Based on data from similar materials

- Effects on fetal development:
  - Test Type: Embryo-fetal development
  - Species: Rat
  - Application Route: Ingestion
  - Result: negative
  - Remarks: Based on data from similar materials

Prednisolone:
- Effects on fertility:
  - Test Type: Fertility/early embryonic development
  - Species: Rat
  - Application Route: Subcutaneous
  - Fertility: NOAEL: 1 mg/kg body weight
  - Result: No effects on fertility.

- Effects on fetal development:
  - Test Type: Embryo-fetal development
  - Species: Mouse
  - Application Route: Oral
  - Developmental Toxicity: LOAEL: 0.5 mg/kg body weight
  - Result: Malformations were observed., Cleft palate

  - Test Type: Embryo-fetal development
  - Species: Rat
  - Application Route: Oral
  - Developmental Toxicity: LOAEL: 30 mg/kg body weight
  - Result: decreased blood formation

  - Species: Rat
  - Application Route: Subcutaneous
  - Developmental Toxicity: NOAEL: 25 mg/kg body weight
  - Result: No effects on fetal development.

Reproductive toxicity - Assessment:
- Some evidence of adverse effects on development, based on animal experiments.
STOT-single exposure
Not classified based on available information.

STOT-repeated exposure
May cause damage to organs (Kidney, inner ear) through prolonged or repeated exposure.
May cause damage to organs (Gastrointestinal tract, Nervous system, Skin, Teeth) through pro-longed or repeated exposure if swallowed.

Components:

Paraffin waxes and Hydrocarbon waxes:

<table>
<thead>
<tr>
<th>Routes of exposure</th>
<th>Assessment</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ingestion</td>
<td>No significant health effects observed in animals at concentrations of 100 mg/kg bw or less.</td>
<td></td>
</tr>
</tbody>
</table>

Neomycin, sulfate (salt):

<table>
<thead>
<tr>
<th>Target Organs</th>
<th>Assessment</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kidney, inner ear</td>
<td>May cause damage to organs through prolonged or repeated exposure.</td>
<td>Based on human experience.</td>
</tr>
</tbody>
</table>

Tetracycline hydrochloride:

<table>
<thead>
<tr>
<th>Routes of exposure</th>
<th>Target Organs</th>
<th>Assessment</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral</td>
<td>Gastrointestinal tract, Nervous system, Skin, Teeth</td>
<td>May cause damage to organs through prolonged or repeated exposure.</td>
<td></td>
</tr>
</tbody>
</table>

Bacitracin:

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>No significant health effects observed in animals at concentrations of 100 mg/kg bw or less.</td>
<td></td>
</tr>
</tbody>
</table>

Prednisolone:

<table>
<thead>
<tr>
<th>Target Organs</th>
<th>Assessment</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bone marrow, Adrenal gland, Liver</td>
<td>Causes damage to organs through prolonged or repeated exposure.</td>
<td></td>
</tr>
</tbody>
</table>

Repeated dose toxicity

Components:

Paraffin waxes and Hydrocarbon waxes:

<table>
<thead>
<tr>
<th>Species</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>Ingestion</td>
<td>90 Days</td>
<td>OECD Test Guideline 408</td>
</tr>
</tbody>
</table>

Neomycin, sulfate (salt):

<table>
<thead>
<tr>
<th>Species</th>
<th>LOAEL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse</td>
<td>30 mg/kg</td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET
according to the Hazardous Products Regulations

Prednisolone / Neomycin / Tetracycline / Bacitracin Formulation

Version 8.0  Revision Date: 09/26/2023  SDS Number: 407505-00022  Date of last issue: 04/04/2023  Date of first issue: 01/07/2016

<table>
<thead>
<tr>
<th>Application Route</th>
<th>Exposure time</th>
<th>Target Organs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subcutaneous</td>
<td>14 d</td>
<td>Kidney</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>NOAEL</th>
<th>LOAEL</th>
<th>Application Route</th>
</tr>
</thead>
<tbody>
<tr>
<td>Guinea pig</td>
<td>50 mg/kg</td>
<td>100 mg/kg</td>
<td>Intramuscular</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Exposure time</th>
<th>Target Organs</th>
</tr>
</thead>
<tbody>
<tr>
<td>30 - 60 Weeks</td>
<td>ear</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>NOAEL</th>
<th>Application Route</th>
</tr>
</thead>
<tbody>
<tr>
<td>Guinea pig</td>
<td>10 mg/kg</td>
<td>Oral</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Exposure time</th>
<th>Target Organs</th>
</tr>
</thead>
<tbody>
<tr>
<td>90 d</td>
<td>ear</td>
</tr>
</tbody>
</table>

| Remarks | No significant adverse effects were reported |

<table>
<thead>
<tr>
<th>Species</th>
<th>NOAEL</th>
<th>Application Route</th>
</tr>
</thead>
<tbody>
<tr>
<td>Guinea pig</td>
<td>100 mg/kg</td>
<td>Subcutaneous</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Exposure time</th>
<th>Target Organs</th>
</tr>
</thead>
<tbody>
<tr>
<td>34 d</td>
<td>Kidney</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>NOAEL</th>
<th>Application Route</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dog</td>
<td>24 mg/kg</td>
<td>Intramuscular</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Exposure time</th>
<th>Target Organs</th>
</tr>
</thead>
<tbody>
<tr>
<td>30 d</td>
<td>ear</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Symptoms</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>hearing loss</td>
<td>mortality observed</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>NOAEL</th>
<th>Application Route</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dog</td>
<td>20 mg/kg</td>
<td>Subcutaneous</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Exposure time</th>
<th>Target Organs</th>
</tr>
</thead>
<tbody>
<tr>
<td>90 d</td>
<td>Kidney</td>
</tr>
</tbody>
</table>

| Remarks | Based on data from similar materials |

**Magnesium stearate:**

<table>
<thead>
<tr>
<th>Species</th>
<th>NOAEL</th>
<th>Application Route</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>&gt; 100 mg/kg</td>
<td>Ingestion</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Exposure time</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>90 Days</td>
<td>Based on data from similar materials</td>
</tr>
</tbody>
</table>

**Tetracycline hydrochloride:**

<table>
<thead>
<tr>
<th>Species</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td></td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET
according to the Hazardous Products Regulations

Prednisolone / Neomycin / Tetracycline / Bacitracin Formulation

<table>
<thead>
<tr>
<th>NOAEL</th>
<th>625 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOAEL</td>
<td>1,250 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>oral (feed)</td>
</tr>
<tr>
<td>Exposure time</td>
<td>13 W</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Liver</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Reduced body weight</td>
</tr>
</tbody>
</table>

Species: Mouse

<table>
<thead>
<tr>
<th>NOAEL</th>
<th>3,750 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOAEL</td>
<td>7,500 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>oral (feed)</td>
</tr>
<tr>
<td>Exposure time</td>
<td>13 W</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Reduced body weight</td>
</tr>
</tbody>
</table>

Species: Rat

<table>
<thead>
<tr>
<th>LOAEL</th>
<th>&gt; 10 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Route</td>
<td>Ingestion</td>
</tr>
<tr>
<td>Exposure time</td>
<td>13 Weeks</td>
</tr>
<tr>
<td>Remarks</td>
<td>Based on data from similar materials</td>
</tr>
</tbody>
</table>

Species: Dog

<table>
<thead>
<tr>
<th>LOAEL</th>
<th>2.5 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>6 Weeks</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Bone marrow</td>
</tr>
</tbody>
</table>

Species: Rabbit

<table>
<thead>
<tr>
<th>LOAEL</th>
<th>1 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>24 Weeks</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Liver</td>
</tr>
</tbody>
</table>

Aspiration toxicity
Not classified based on available information.

Components:

Tetracycline hydrochloride:
Not applicable
Experience with human exposure

**Components:**

**Neomycin, sulfate (salt):**
- **Skin contact:** Symptoms: Sensitization
  Remarks: May irritate skin.
- **Eye contact:** Remarks: May cause eye irritation.
- **Ingestion:** Symptoms: Nausea, Vomiting, Diarrhea, tinnitus, hearing loss, Loss of balance

**Tetracycline hydrochloride:**
- **Ingestion:** Target Organs: Teeth
  Symptoms: Gastrointestinal disturbance, Nausea, Vomiting, Diarrhea, Liver effects, skin rash, central nervous system effects
  Remarks: May cause sensitization of susceptible persons.
  May cause photosensitization.
  Based on Human Evidence

**prednisolone:**
- **Ingestion:** Symptoms: sodium retention, Headache, Vertigo, fluid retention, subcutaneous bleeding, striae, skin atrophy, menstrual irregularities

**SECTION 12. ECOLOGICAL INFORMATION**

**Ecotoxicity**

**Components:**

**Paraffin waxes and Hydrocarbon waxes:**
- **Toxicity to fish:** LL50 (Pimephales promelas (fathead minnow)): > 100 mg/l
  Exposure time: 96 h
  Method: OECD Test Guideline 203
  Remarks: Based on data from similar materials

- **Toxicity to daphnia and other aquatic invertebrates:** EC50 (Daphnia magna (Water flea)): > 1,000 mg/l
  Exposure time: 48 h
  Remarks: Based on data from similar materials

- **Toxicity to algae/aquatic plants:** NOEC (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l
  Exposure time: 72 h
  Method: OECD Test Guideline 201
  Remarks: Based on data from similar materials

- **Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):** NOEC (Daphnia magna (Water flea)): 10 mg/l
  Exposure time: 21 d
  Remarks: Based on data from similar materials

**Neomycin, sulfate (salt):**
Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)) > 72 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

LC50 (Americamysis): 39 mg/l
Exposure time: 96 h
Method: US-EPA OPPTS 850.1035

Toxicity to algae/aquatic plants:
EC50 (Anabaena flos-aquae (cyanobacterium)): 0.00075 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Anabaena flos-aquae (cyanobacterium)): 0.0003 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

EC50 (Pseudokirchneriella subcapitata (green algae)): 0.0099 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 0.0022 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to microorganisms:
EC50 (Natural microorganism): 107.6 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

EC10 (Natural microorganism): 2.8 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Magnesium stearate:
Toxicity to fish: LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l
Exposure time: 48 h
Method: DIN 38412
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates:
EL50 (Daphnia magna (Water flea)): > 1 mg/l
Exposure time: 47 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials
No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants:
EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
SAFETY DATA SHEET
according to the Hazardous Products Regulations

Prednisolone / Neomycin / Tetracycline / Bacitracin Formulation

Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials
No toxicity at the limit of solubility.

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

Toxicity to microorganisms: EC10 (Pseudomonas putida): > 100 mg/l
Exposure time: 16 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

Tetracycline hydrochloride:

Toxicity to algae/aquatic plants: EC50 (Anabaena flos-aquae (cyanobacterium)): 6.2 mg/l
Exposure time: 72 h
NOEC (Anabaena flos-aquae (cyanobacterium)): 2.5 mg/l
Exposure time: 72 h
EC50 (Pseudokirchneriella subcapitata (green algae)): 3.31 mg/l
Exposure time: 72 h
NOEC (Pseudokirchneriella subcapitata (green algae)): 0.032 mg/l
Exposure time: 72 h
EC50 (Microcystis aeruginosa (blue-green algae)): 0.09 mg/l
Exposure time: 7 d
Exposure time: 72 h
Exposure time: 72 h
Exposure time: 72 h

Toxicity to microorganisms: EC50: 0.08 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Bacitracin:

Toxicity to daphnia and other aquatic invertebrates: EC50 (Artemia salina (brine shrimp)): 21.8 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants: EC50 (Anabaena flos-aquae (cyanobacterium)): 10 mg/l
Exposure time: 10 d
Method: OECD Test Guideline 201

Prednisolone:

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): > 85 mg/l
aquatic invertebrates

Toxicity to algae/aquatic plants:

- NOEC (Pseudokirchneriella subcapitata (green algae)): 160 mg/l
  Exposure time: 72 h

- EC50 (Pseudokirchneriella subcapitata (green algae)): > 160 mg/l
  Exposure time: 72 h

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):

- NOEC (Ceriodaphnia dubia (water flea)): 0.23 mg/l
  Exposure time: 7 d

Persistence and degradability

Components:

Paraffin waxes and Hydrocarbon waxes:

- Biodegradability: Result: Not readily biodegradable.
  Biodegradation: 31 %
  Exposure time: 28 d
  Method: OECD Test Guideline 301F
  Remarks: Based on data from similar materials

Neomycin, sulfate (salt):

- Biodegradability: Result: rapidly degradable
  Biodegradation: 50 %
  Exposure time: 1.2 d
  Method: OECD Test Guideline 314

Magnesium stearate:

- Biodegradability: Result: Not biodegradable
  Remarks: Based on data from similar materials

Bioaccumulative potential

Components:

Paraffin waxes and Hydrocarbon waxes:

- Partition coefficient: n-octanol/water: log Pow: 5.3 - 6.7

Neomycin, sulfate (salt):

- Partition coefficient: n-octanol/water: log Pow: < -2

Magnesium stearate:

- Partition coefficient: n-octanol/water: log Pow: > 4

Tetracycline hydrochloride:
SAFETY DATA SHEET
according to the Hazardous Products Regulations

Prednisolone / Neomycin / Tetracycline / Bacitracin Formulation

Partition coefficient: n-octanol/water

Bacitracin:
 Partition coefficient: n-octanol/water : log Pow: -0.8
 pH: 7

Prednisolone:
 Partition coefficient: n-octanol/water : log Pow: 1.46

Mobility in soil
No data available

Other adverse effects
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
 Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
 If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG
UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
 (Neomycin, sulfate (salt), tetracycline hydrochloride)

Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

IATA-DGR
UN/ID No. : UN 3077
Proper shipping name : Environmentally hazardous substance, solid, n.o.s.
 (Neomycin, sulfate (salt), Tetracycline hydrochloride)

Class : 9
Packing group : III
Labels : Miscellaneous
Packing instruction (cargo aircraft) : 956
Packing instruction (passenger aircraft) : 956
Environmentally hazardous : yes
IMDG-Code
UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(Neomycin, sulfate (salt), Tetracycline hydrochloride)
Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Domestic regulation

TDG
UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(Neomycin, sulfate (salt), Tetracycline hydrochloride)
Class : 9
Packing group : III
Labels : 9
ERG Code : 171
Marine pollutant : yes (Neomycin, sulfate (salt), Tetracycline hydrochloride)

Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

The ingredients of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined

SECTION 16. OTHER INFORMATION

Full text of other abbreviations
ACGIH : USA. ACGIH Threshold Limit Values (TLV)
CA BC OEL : Canada. British Columbia OEL
CA QC OEL : Québec. Regulation respecting occupational health and safe-
SAFETY DATA SHEET
according to the Hazardous Products Regulations

Prednisolone / Neomycin / Tetracycline / Bacitracin Formulation

Version: 8.0
Revision Date: 09/26/2023
SDS Number: 407505-00022
Date of last issue: 04/04/2023
Date of first issue: 01/07/2016

Schedule 1, Part 1: Permissible exposure values for airborne contaminants

ACGIH / TWA : 8-hour, time-weighted average
CA AB OEL / TWA : 8-hour Occupational exposure limit
CA BC OEL / TWA : 8-hour time weighted average
CA QC OEL / TWAEV : Time-weighted average exposure value

AIIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; ICS0 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet:

Revision Date: 09/26/2023
Date format: mm/dd/yyyy

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided
relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

CA / Z8